GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » TuHURA Biosciences Inc (NAS:HURA) » Definitions » Total Equity

HURA (TuHURA Biosciences) Total Equity : $1.70 Mil (As of Sep. 2024)


View and export this data going back to 2024. Start your Free Trial

What is TuHURA Biosciences Total Equity?

TuHURA Biosciences's total equity for the quarter that ended in Sep. 2024 was $1.70 Mil.

This is Residual interest, including minority interest, that remains in the assets of the enterprise after deducting its liabilities. Equity is increased by owners’ investments and by comprehensive income, and it is reduced by distributions to the owners.


TuHURA Biosciences Total Equity Historical Data

The historical data trend for TuHURA Biosciences's Total Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

TuHURA Biosciences Total Equity Chart

TuHURA Biosciences Annual Data
Trend Dec21 Dec22 Dec23
Total Equity
-0.75 12.30 -1.56

TuHURA Biosciences Quarterly Data
Dec21 Mar22 Dec22 Mar23 Dec23 Mar24 Jun24 Sep24
Total Equity Get a 7-Day Free Trial 7.17 -1.56 -6.07 -6.96 1.70

TuHURA Biosciences Total Equity Calculation

Total Equity and Total Liabilities are the two components for Total Assets.

TuHURA Biosciences's Total Equity for the fiscal year that ended in Dec. 2023 is calculated as

Total Equity=Total Assets(Q: Dec. 2023 )-Total Liabilities(Q: Dec. 2023 )
=4.362-5.921
=-1.56

TuHURA Biosciences's Total Equity for the quarter that ended in Sep. 2024 is calculated as

Total Equity=Total Assets(Q: Sep. 2024 )-Total Liabilities(Q: Sep. 2024 )
=4.14-2.445
=1.70

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


TuHURA Biosciences Total Equity Related Terms

Thank you for viewing the detailed overview of TuHURA Biosciences's Total Equity provided by GuruFocus.com. Please click on the following links to see related term pages.


TuHURA Biosciences Business Description

Traded in Other Exchanges
N/A
Address
10500 University Center Drive, Suite 110, Tampa, FL, USA, 33612
TuHURA Biosciences Inc is a Phase 3 registration stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. The company's personalized cancer vaccine candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. It is preparing to initiate a single randomized placebo-controlled Phase 3 registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda (pembrolizumab) in first-line treatment for advanced or metastatic Merkel Cell Carcinoma.